Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brain Biomarker on Inflammation Response
NCT03271814Phase 1Withdrawn
- Sponsor
- University of Maryland, Baltimore
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Biologic
01
Overview
Phase 1, randomised, double-blind trial of lipopolysaccharide endotoxin (3 arms), sponsored by University of Maryland, Baltimore. Primary endpoint: Interleukin-6. Planned start Jan 2025; status: withdrawn.
02
Drugs
lipopolysaccharide endotoxin
Beyond the preview
Go deeper on NCT03271814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03271814.